Amgen 2004 Annual Report Download - page 36

David Beier
Senior Vice President,
Global Government Affairs
Fabrizio Bonanni
Senior Vice President,
Manufacturing
Hassan A. Dayem
Senior Vice President and
Chief Information Offi cer
Willard Dere
Senior Vice President,
Global Development and
Chief Medical Offi cer
Dennis M. Fenton
Executive Vice President,
Operations and Corporate
Compliance Offi cer
David V. Goeddel
Senior Vice President and
Site Leader, Amgen San Francisco
Rolf K. Hoffmann
Senior Vice President,
Amgen Europe
Brian M. McNamee
Senior Vice President,
Human Resources
Joseph P. Miletich
Senior Vice President,
Research and Preclinical Development
George J. Morrow
Executive Vice President,
Global Commercial Operations
Richard D. Nanula
Executive Vice President and
Chief Financial Offi cer
Roger M. Perlmutter
Executive Vice President,
Research and Development
David J. Scott
Senior Vice President,
General Counsel and Secretary
Kevin W. Sharer
Chairman of the Board,
Chief Executive Offi cer
and President
Senior Management
Corporate Offi ce
One Amgen Center Drive
Thousand Oaks, California 91320-1799
[phone]
Amgen 2004 Annual Report Summary and Availability of SEC Form 10-K
This information is a summary and does not provide complete information; it should be
considered along with the Company’s Annual Report on Form 10-K for the year ended
December 31,2004. A copy of the Company’s Form 10-K for the year ended December
31,2004, fi led with the Securities and Exchange Commission, is available without
charge, upon written request to Investor Relations, Amgen, One Amgen
Center Drive, Thousand Oaks, California 91320-1799, by calling (800) 84-AMGEN,
or by accessing the Company’s Web site at www.amgen.com.
Transfer Agent and Registrar
American Stock Transfer & Trust Company
59 Maiden Lane
New York, New York 10038
Stockholder Inquiries
Inquiries related to stock transfers or lost certifi cates should be directed to American
Stock Transfer & Trust Company, [phone] or [phone]. General
information regarding the Company and recent news releases can be obtained by
contacting Amgen’s automated stockholder information line at (800) 84-AMGEN
or by accessing the Company’s Web site at www.amgen.com.
Independent Registered Public Accounting Firm
Ernst & Young LLP, Los Angeles, California
Annual Meeting
The Annual Meeting will be held on Wednesday, May 11,2005, at 2 p.m. at
the Fairmont Olympic Hotel, 411 University Street, Seattle, Washington 98101.
Price Range of Common Stock
The Company’s common stock trades on The NASDAQ Stock Market under
the symbol AMGN. No cash dividends have been paid on the common stock to
date, and the Company currently intends to utilize any earnings for development
of the Company’s business and for repurchases of its common stock.
The following table sets forth, for the fi scal periods indicated, the range of
high and low closing sales prices of the common stock as quoted on The NASDAQ
Stock Market for the years 2004 and 2003:
2004 2003
High Low High Low
4th Quarter $64.76 $52.70 $67.14 $57.62
3rd Quarter 59.98 53.23 71.54 64.52
2nd Quarter 60.43 52.82 67.50 57.60
1st Quarter 66.23 57.83 58.87 48.88
Trademarks Listed in this Report
Amgen, Aranesp®
,EPOGEN® ,INFERGEN® , Kepivance™ , Kineret® , Mimpara® ,
Neulasta® ,NEUPOGEN® , and Sensipar® are trademarks of Amgen Inc. ENBREL®
is a trademark of Amgen’s subsidiary, Immunex Corporation.
Hotlines
Customer Service Hotline (800) 28-AMGEN
Investor Materials Hotline (800) 84-AMGEN
Jobline [phone]
Medical Information Connection (800) 77-AMGEN
Reimbursement Hotline [phone]
Clinical Safety Hotline [phone]
Stockholder Information
Board of Directors
David Baltimore
President,
California Institute of Technology
Frank J. Biondi, Jr.
Senior Managing Director,
WaterView Advisors LLC
Jerry D. Choate
Retired Chairman and
Chief Executive Offi cer,
The Allstate Corporation
Edward V. Fritzky
Retired Chairman and
Chief Executive Offi cer,
Immunex Corporation
Frederick W. Gluck
Former Managing Director,
McKinsey & Company, Inc.
Frank C. Herringer
Former Chairman of the Board,
Transamerica Corporation
Franklin P. Johnson, Jr.
General Partner,
Asset Management Partners
Gilbert S. Omenn
Professor of Internal Medicine,
Human Genetics and Public Health,
University of Michigan, and
Former Chief Executive Offi cer,
University of Michigan Health System
Judith C. Pelham
President Emeritus,
Trinity Health
Adm. J. Paul Reason,
USN (retired)
President and
Chief Operating Offi cer,
Metro Machine Corporation
Donald B. Rice
Chairman of the Board,
President and Chief
Executive Offi cer,
Agensys, Inc.
Leonard D. Schaeffer
Chairman of the Board,
WellPoint, Inc.
Kevin W. Sharer
Chairman of the Board,
Chief Executive Offi cer
and President,
Amgen Inc.
Design: VSA Partners, Inc. Select photography: Alessandra Petlin Printing: Cenveo Anderson Lithograph
Amgen 2004 Annual Report page 34